STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
227: Biden's Covid declaration, twilight of the SPAC, & genome editing 2.0
Heidi Tworek, a professor at the University of British Columbia and expert on public health communication, joins us to discuss President Biden's declaration that "the pandemic is over" and how leaders around the world are talking about Covid-19 as it enters its third year. We’ll also discuss the latest news in the life sciences, including the twilight of the SPAC boom, the coming evolution of genome editing, and the next big trial in Alzheimer’s disease.
226: Pharma's telehealth gold mine, the return of the biotech IPO, & a merger deferred
Our colleague Katie Palmer joins us to explain a burgeoning trend in pharmaceutical advertising that has health policy experts alarmed. We also discuss the White House's investment in biotech, a bellwether IPO, and the latest twist in the Merck-Seagen saga.
225: Illumina's $8 billion limbo, a new treatment for ALS, & Emirati biotech funding
Our colleague Matthew Herper joins us to discuss how Illumina, the biggest company in genomic sequencing, got into an $8 billion predicament. We also discuss a dramatic development for a new ALS treatment, the latest in cancer research, and a well-funded new player in biotech venture capital.
224: The anti-aging research boom, the Godfather of biotech, & the future of Biogen
Our colleague Megan Molteni joins us to explain the scientific discoveries, rampant hype, and Silicon Valley billions behind the burgeoning field of longevity research. Then, we discuss the remarkable career of Stelios Papadopoulos, the venerated Godfather of biotech who faces the daunting task of saving Biogen.
223: Fauci's non-retirement, grading biotech VCs, & a bellwether IPO
Our colleague Helen Branswell joins to explain the Covid-19 booster debate, the Biden Administration’s monkeypox response, and the long career of the soon-to-step-down Anthony Fauci. We also discuss the latest news in the life sciences, including a milestone for gene therapy, the tentative return of an IPO market, and the venture capital league table.
222: Private equity in autism care, a watershed FDA approval, & the future of ALS treatment
First, STAT's Tara Bannow joins us to discuss how private equity's mounting interest in autism care has created an untenable situation for many parents in the U.S. We also explain the implications of Bluebird Bio's long-awaited FDA approval, a controversial treatment for ALS, and the ups and downs of Merck's reported interest in buying Seagen.
Hi i love the podcast❤️❤️❤️❤️❤️❤️
Wrong Tone On the Murder for Hire
It sounds like someone was killed. If it was one of your close relatives you would be furious about the tone. Murder is serious, not funny, although I do understand that it’s not usually your beat. You come off as young, naive and lacking in character and wisdom.
Great for people who follow the biotech industry
Does a great job of reporting on and discussing the important developments in the biotech industry.